Tuesday, March 30, 2021 12:20:45 PM
The ultra-micronized PEA direction of the company, now substantiated by Bokhari with the FSD Pharma contract in Europe with Innovet Italia S.R.L., seems likely worthy to continue (if in fact legit), but maybe a company decision to 'cut its losses' there and to move back into mj and psych drugs will be appropriate, or, to maintain ultra-micro PEA research and development along with and as its own division of FSD Pharma. The two later (mj, psych) certainly grab greater Market attention.
(irrespective of hounding harassment that will suggest that no one cares)
(c) copyright 2021
Recent HUGE News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/07/2024 12:31:36 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/20/2024 11:01:57 AM
- GBB Maintains Strong Position in its Ongoing Lawsuit with FSD Pharma After Court Refuses to Dismiss Case • GlobeNewswire Inc. • 01/11/2024 06:10:23 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/05/2024 05:15:17 AM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM